Publication: Myoepithelial tumor of soft tissue and bone: A current perspective
Authors
Verma, Anuj ; Rekhi, Bharat
item.page.secondaryauthor
item.page.director
Publisher
Universidad de Murcia. Departamento de Biología Celular e Histología
publication.page.editor
publication.page.department
DOI
DOI: 10.14670/HH-11-879
item.page.type
info:eu-repo/semantics/article
Description
Abstract
Myoepithelial tumor (MET) of soft tissue and
bone is an unusual tumor of uncertain differentiation and
histogenesis, but lately has been recognized as a distinct
tumor entity. This tumor forms a morphologic continuum
with a mixed tumor and a parachordoma, but is different
from an extra-axial chordoma or chordoma periphericium.
METs display a range of histopathologic features,
including architectural arrangements/growth patterns, cell
types and intervening stroma, leading to their several
differential diagnoses. Presently, moderate nuclear atypia
is the acceptable criterion to differentiate a myoepithelial
carcinoma from a myoepithelioma. Immunohistochemical
(IHC) stains, including epithelial antibody markers, along
with S100 protein and GFAP are necessary in confirming
a diagnosis of a MET. Certain METs are associated with
loss of INI1/SMARCB1. Lately, certain specific
“molecular signatures” been described underlying METs,
identification of which that can further aid in their
accurate diagnosis and in differentiating these tumors
from their diagnostic mimics. Complete surgical resection
forms the treatment mainstay, irrespective of a
myoepithelioma or a myoepithelial carcinoma. This
review will focus upon clinicopathologic, immunohistochemical and molecular features of METs of soft tissue
and bone, along with their differential diagnoses and
diagnostic implications.
publication.page.subject
Citation
item.page.embargo
Ir a Estadísticas
Este ítem está sujeto a una licencia Creative Commons. CC BY 4.0